Funded by the manufacturer: what to check beyond the disclosure
By ClinicalStudyConnect.com Research Desk. Updated September 26, 2026.
Picture a news story about a new study. Near the bottom, one line reads, “This trial was funded by the manufacturer.” You wonder whether that changes how much to trust it.
The short answer: a funding disclosure only tells you who paid. Beyond it, check what the funder’s role was, whether the protocol and analysis plan can be found, whether the trial was registered, whether participant data availability is stated, and whether the authors’ conflicts are listed. These checks show what you can verify. They do not prove a result is right or wrong.
Stage 1: What a funding disclosure does and does not tell you
A disclosure answers one question: who paid for the trial? That is useful, but it leaves out what the payer was allowed to do.
The CONSORT 2025 reporting guideline treats funding as more than a name. Its checklist asks trial reports to describe the sources of funding and the funder’s role in the trial. It separately asks for the financial and other conflicts of interest of the report’s authors. So a complete report should say who paid and what part they played.
A trial paid for by a manufacturer is not automatically flawed. A trial with no manufacturer involved is not automatically sound. Funding is one piece of context to read alongside the design.
Stage 2: The protocol, the plan written before the results
A protocol is the trial’s written plan. It describes who can join, what each group receives, which outcomes will be measured, and how the results will be analyzed. A statistical analysis plan is the detailed set of rules for how the numbers will be analyzed.
These documents matter because they let a reader compare what was planned with what was reported. SPIRIT is a minimum set of recommendations for reporting the protocol of a randomized trial, with a 34-item checklist. CONSORT 2025, which guides how trial results are reported, has a 30-item checklist. It includes an item asking where the full protocol and statistical analysis plan can be accessed.
CONSORT 2025 also includes an item on trial registration. A trial registry is a public database where a trial is listed. ClinicalTrials.gov is one such registry, and it publishes a guide on reading study results. A registration number gives you a place to look for the trial’s listed details, so you can compare them with the published paper.
The design also affects how much weight a result deserves. Our page on trial comparator choice: placebo, usual care, and active treatment covers one design choice worth understanding alongside funding.
Stage 3: Data access and what “available” can mean
CONSORT 2025 also asks reports to say whether de-identified participant data, statistical code, and other materials are available, and where and how they can be accessed. De-identified means personal details have been removed.
A practical caution: a data availability statement is not the same as being able to get the data. Read the wording closely and note whether it gives a specific place or process to follow, or only a general statement.
Data access is about checking what a report lets others do, not about doing your own analysis. When results look striking, our page on absolute versus relative risk in a trial works through the same numbers in both forms, which helps when reading how results are presented.
Funding review worksheet
Use this worksheet with any trial report. Write down each answer. If you can’t find something, mark it “not found.” That is a finding, not a failure.
- Who paid? Find the funding statement. Note every funder named.
- What was the funder’s role? Look for a sentence on whether the funder took part in design, data collection, analysis, or the decision to publish. If the report does not say, write “role not stated.”
- Are the authors’ conflicts listed? Look for a disclosure for each author, not one blanket line.
- Is there a registration number? If so, look up the registry record and note what it lists as the main outcomes.
- Do the registry and the paper match? Compare the outcomes listed in the registry with the outcomes the paper emphasizes. Note any difference, and whether the paper explains it.
- Can you find the protocol and analysis plan? Note where the report says they can be accessed. If it gives no location, write “not stated.”
- What does the data statement say? Note whether participant data, code, and materials are described as available, and how to request them.
- What does the comparison group look like? Note whether it was a placebo, usual care, or another treatment.
- Which numbers are given? Note whether results are shown as absolute numbers, relative changes, or both.
Then count how many items are “clear,” “partly clear,” and “not found.” That tally describes how transparent the report is. It does not tell you whether the treatment works.
Warning boundaries: what this worksheet cannot tell you
- It cannot prove bias or rule it out. A complete worksheet does not make a trial trustworthy. A gap does not make it untrustworthy.
- It cannot tell you whether a treatment is safe or effective for you. Trials describe groups of participants, not individuals.
- It cannot replace an expert reading of the methods. Study design and statistics still matter.
- It depends on what the report says. The worksheet checks what is reported and findable. It cannot confirm that what a report says matches what happened in the trial.
Decision path: what to do with your answers
- If the funder’s role is not stated, treat the report as less transparent. Look for the registry record or a companion paper before relying on its conclusions.
- If the registry and the paper emphasize different outcomes, look for the authors’ explanation. If there is none, treat the headline result with more caution.
- If the protocol cannot be found, read the paper’s methods section more carefully. A librarian or the corresponding author may be able to point you to it.
- If most items are clear, you still need to read the results and consider the comparison group and effect sizes.
A safe next step: if the trial relates to a treatment you use or are considering, bring your completed worksheet to your doctor or pharmacist. Ask what the results mean for your situation. Do not start, stop, or change any medicine based on a single trial report.
Sources and limits
What this page draws on: the CONSORT and SPIRIT site describes SPIRIT (protocol reporting, 34 items) and CONSORT (results reporting, 30 items). The CONSORT 2025 items on registration, protocol and analysis plan access, data availability, funding and funder role, and author conflicts are paraphrased from published summaries of the checklist, not quoted. ClinicalTrials.gov is named as an example public registry.
What this page does not do: assess any specific manufacturer-funded trial. Nothing here says funded trials are more or less reliable than others.
Educational disclaimer: this article is general educational information about reading clinical research. It is not medical advice and does not diagnose or recommend treatment. Talk with a qualified health professional about your own health. If you think you are having a medical emergency, call your local emergency number. Clinical Study Connect is an independent educational publication. See our medical disclaimer and the Clinical Study Connect home page for more.